key: cord-0733739-w90h3cty
authors: Leeman, Jonathan E.; Nguyen, Paul L.
title: Less Is More During COVID 19
date: 2020-10-01
journal: Int J Radiat Oncol Biol Phys
DOI: 10.1016/j.ijrobp.2020.07.010
sha: 102bb1b21890f64d3968d43f4e2686afc8fd741c
doc_id: 733739
cord_uid: w90h3cty

nan

Thus, I would have treated the patient in early March with stereotactic body radiation therapy and androgen deprivation therapy (ADT) because of the known survival benefits of ADT, the potential protective effect of ADT on COVID-19especific mortality, and because the patient is estimated to live >10 years. Now that his treatment has been delayed, I would treat him with shorter-term ADT based on the DART 01/05 randomized trial, which demonstrated that long-term ADT increased cardiovascular events by 2.1-fold and the dominant mode of death in highrisk prostate cancer is other-cause mortality. 2 I would continue to offer stereotactic body radiation therapy to reduce hospital exposure to COVID-19 if it is in the peak of a second wave (estimated 7% increased risk of contracting COVID-19 from 5-vs 20-fraction radiation therapy from increased cumulative hospital exposure). I would not give nodal radiation therapy based multiple negative randomized trials, while we await the results of RTOG 0924 . For high-risk disease, we would offer ADT for 2 years and 28 fractions of intensity modulated radiation therapy plus a brachytherapy boost per ASCENDE-RT. 3 If procedures were being limited due to a COVID-19 surge we would use 60 Gy in 20 fractions. We do not typically treat the pelvic lymph nodes prophylactically for localized highrisk disease except for young patients at the highest end of the risk spectrum, and we await the results of RTOG 09-24. We would not offer stereotactic body radiation therapy for high-risk disease off trial, but a future NRG trial may be testing stereotactic body radiation therapy for high risk.

Without symptoms or potential exposures, we would not routinely test for SARS-CoV-2, but we would screen daily and test as needed. The pandemic has led us toward more use of moderate hypofractionation, but we continue to favor combination therapy per ASCENDE-RT for high-risk or higher volume unfavorable intermediate-risk patients.

Delaying dilemmas: Coronavirus complications impacting the management of prostate cancer

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a doseescalated external beam boost for high-and intermediate-risk prostate cancer

What would you do? Continue the discussion on Twitter at #gyzone, and take the poll at www.redjournal.org/poll